Merck & Co., Inc. due diligence
Who Merck & Co., Inc. (MRK) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.
At a glance
Merck & Co., Inc. (MRK) is a large accelerated filer incorporated in New Jersey, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends December 31. It has also filed as Merck & Co. Inc. and SCHERING PLOUGH CORP.
For the fiscal year ended December 31, 2025, its 10-K reported revenue of $65.0B, up 1.3% from the year before, net income of $18.3B, and total assets of $137B.
In the twelve months to November 20, 2026 it made 150 filings on EDGAR, including 1 annual report, 3 quarterly reports, 9 current reports on Form 8-K, and 81 Form 4 insider filings, plus 6 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (4), officer or director changes (2), and other events (2).
Annual results
| Fiscal year ended | Revenue | Net income | Total assets |
|---|---|---|---|
| 2025-12-31 | $65.0B +1.3% | $18.3B +6.6% | $137B |
| 2024-12-31 | $64.2B +6.7% | $17.1B +4589.6% | $117B |
| 2023-12-31 | $60.1B | $365M | $107B |
| Filing | Filed | Period | Accession |
|---|---|---|---|
| Annual report (10-K) | 2026-02-24 | 2025-12-31 | 0000310158-26-000063 |
| Quarterly report (10-Q) | 2026-11-04 | 2026-09-30 | 0000310158-26-000248 |
| Current report (8-K) | 2026-11-18 | 2026-11-16 | 0000310158-26-000255 |
Filing activity
| Filed | Form | Document | Period |
|---|---|---|---|
| 2026-11-18 | 8-K | Current report on Form 8-K | 2026-11-16 |
| 2026-11-16 | 4 | Form 4 insider filing | 2026-11-12 |
| 2026-11-13 | 13F-HR | Form 13F-HR filing | 2026-09-30 |
| 2026-11-12 | 144 | Form 144 notice of proposed sale | |
| 2026-11-04 | 10-Q | Quarterly report | 2026-09-30 |
| 2026-11-03 | 4 | Form 4 insider filing | 2026-11-01 |
| 2026-11-03 | 3 | Form 3 initial ownership filing | 2026-11-01 |
| 2026-11-02 | 144 | Form 144 notice of proposed sale | |
| 2026-10-29 | 8-K | FORM 8-K | 2026-10-29 |
| 2026-10-22 | 3/A | Form 3/A filing | 2026-05-01 |
The full due-diligence dossier on Merck & Co., Inc.
The free view above is the filing record: identity, annual results and the last year of filings. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.
Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.